Have a personal or library account? Click to login
Pneumonitis with amivantamab in squamous cell lung cancer with EGFR exon 20 insertion mutation: a case report Cover

Pneumonitis with amivantamab in squamous cell lung cancer with EGFR exon 20 insertion mutation: a case report

Forum of Clinical Oncology
Volume 14 (2023): Issue 3 (December 2023)
By: Margarida Melo Cruz,  Ana Filipa Silva,  Sara Raimundo and  Teresa Gomes  
Open Access
|Dec 2024

Figures & Tables

Figure 1:

CT scan at diagnosis showing a right upper lobe lesion with right upper and medium lobes collapse.
CT scan at diagnosis showing a right upper lobe lesion with right upper and medium lobes collapse.

Figure 2:

CT scan after treatment with amivantamab showing scattered ground glass opacities in the left lung.
CT scan after treatment with amivantamab showing scattered ground glass opacities in the left lung.

Figure 3:

CT scan after corticosteroid treatment showing resolution of the previous opacities.
CT scan after corticosteroid treatment showing resolution of the previous opacities.

Figure 4:

CT scan after reintroduction of amivantamab, without evidence of toxicity and stable disease.
CT scan after reintroduction of amivantamab, without evidence of toxicity and stable disease.
DOI: https://doi.org/10.2478/fco-2023-0039 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 39 - 42
Submitted on: Apr 16, 2024
Accepted on: Jul 3, 2024
Published on: Dec 4, 2024
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
lung cancer,
epidermal growth factor receptor,
non-small cell lung cancer,
case report,
exon 20 insertion,
squamous cell lung cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2024 Margarida Melo Cruz, Ana Filipa Silva, Sara Raimundo, Teresa Gomes, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 14 (2023): Issue 3 (December 2023)Next article